Naoya Matsumura

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rajiv Agarwal, Wanzhu Tu, Alfredo E. Farjat et al. · Annals of Internal Medicine · 2023 · 88 citations

Medicine, Pharmacology, Pharmacotherapy +17

A Novel Highly Potent Autotaxin/ENPP2 Inhibitor Produces Prolonged Decreases in Plasma Lysophosphatidic Acid Formation In Vivo and Regulates Urethral Tension

Hiroshi Saga, Akira Ohhata, Akio Hayashi et al. · PLoS ONE · 2014 · 57 citations · Full text

Life Sciences, Biochemistry, Pharmacology +13

Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF1) receptor antagonists

Tetsuji Saito, Tetsuo Obitsu, Chiaki Minamoto et al. · Bioorganic & Medicinal Chemistry · 2011 · 47 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +7

Beneficial effect of stopping smoking on future cardiac events in male smokers with previous myocardial infarction.

Isao Satō, Masayuki Nishida, Kohichi Okita et al. · Japanese Circulation Journal · 1992 · 37 citations · Full text

Medicine, Cardiology, Behavioral Risk Factor Modification +13